ClinicalTrials.gg
CompletedNCT04003636KEYNOTE-966Updated Mar 24, 2026Results posted

Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)

A Phase 3 interventional study of Pembrolizumab and Gemcitabine in Biliary Tract Carcinoma, sponsored by Merck Sharp & Dohme LLC. Completed at 185 sites in 24 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-24.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,069
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing pembrolizumab in Cholangiocarcinoma — 3 open to participants now, 5 under way, 1 of them phase 3. pembrolizumab · Cholangiocarcinoma.

Enrollment
2nd of 12
1,069 · median 91
Started
2019
with 2 others
Phase 3
3 of 12
none open now
Registered
5th of 12
by date
Lead sponsor
3 of 12
Merck Sharp & Dohme LLC

Among the 12 studies testing pembrolizumab in Cholangiocarcinoma, this one is the 2nd largest by enrollment, is one of 3 that started in 2019, is one of 3 in phase 3, and was the 5th registered.

Cholangiocarcinoma

825 studies on the registry are indexed under Cholangiocarcinoma; 288 are open to participants now.

Browse Cholangiocarcinoma studies →

Open to participants now

3 of the 12 studies testing pembrolizumab in Cholangiocarcinoma are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About pembrolizumab

pembrolizumab: first FDA approval 2014 (KEYTRUDA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 211 Cholangiocarcinoma studies recruiting now, 141 (67%) set no upper age limit and 49 (23%) stop at 75 or younger; 10 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing pembrolizumab in Cholangiocarcinoma, or all of them as a file.
02

Study summary

This is a study of pembrolizumab plus gemcitabine/cisplatin versus placebo plus gemcitabine/cisplatin as first-line therapy in participants with advanced and/or unresectable biliary tract carcinoma. The primary hypothesis is pembrolizumab plus gemcitabine/cisplatin is superior to placebo plus gemcitabine/cisplatin with respect to overall survival (OS).

03

Conditions studied

  • Biliary Tract Carcinoma

Keywords

  • Programmed cell death 1 (PD-1)
  • Pembrolizumab
  • Cholangiocarcinoma
  • Gallbladder cancer
  • Checkpoint inhibitor
  • Immunotherapy
  • Biliary
  • Keytruda
  • Bile Duct Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has confirmed diagnosis of advanced () and/or unresectable (locally advanced) biliary tract cancer (intra-or extrahepatic cholangiocarcinoma or gallbladder cancer)
  • Has based on (RECIST 1.1), as determined by the site investigator
  • Participants with a history of or can be enrolled if they meet study criteria
  • Is able to provide sample or newly obtained core or excisional biopsy of a tumor lesion
  • Has a of greater than 3 months
  • Has adequate organ function

Exclusion criteria

Exclusion Criteria

  • Has had previous systemic therapy for advanced () or unresectable (locally advanced) biliary tract cancer (intra-or extra hepatic cholangiocarcinoma or gallbladder cancer)
  • Has ampullary cancer
  • Has small cell cancer, neuroendocrine tumors, lymphoma, sarcoma, mixed tumor histology and/or mucinous cystic neoplasms
  • Has received prior therapy with an anti-programmed cell death 1 (), anti- programmed cell death ligand 1 or 2 (anti-PD-L1, anti-PD-L2) agent or with an agent directed to another stimulatory or coinhibitory T-cell receptor (e.g., cytotoxic T-lymphocyte-associated protein 4 [CTLA-4], OX-40, CD137)
  • Has a known history of, or any evidence of, central nervous system (CNS) metastases and/or carcinomatous meningitis, as assessed by local site investigator
  • Has had an allogenic tissue/solid organ transplant
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
1,069 participants (actual)

Study arms

  • Experimental
    Arm A (Pembrolizumab+Chemotherapy)

    Participants receive pembrolizumab, 200 mg intravenous (IV) infusion, every 3 weeks (Q3W), Day 1 of each 3-week cycle for up to 35 cycles PLUS gemcitabine, 1000 mg/m\^2, IV infusion Q3W, Day 1 and Day 8 of each 3-week cycle until progressive disease or unacceptable toxicity PLUS cisplatin, 25 mg/m\^2 IV infusion, Q3W, Day 1 and Day 8 of each 3-week cycle for up to 8 cycles. Eligible participants who stop the initial course of pembrolizumab with stable disease (SD) or better but progress after discontinuation will initiate a second course of pembrolizumab 200 mg IV Q3W, Day 1 of each 3-week cycle for up to 17 cycles. Treatment with gemcitabine can be stopped at anytime in first or second course due to toxicity or disease progression.

    Biological: Pembrolizumab · Drug: Gemcitabine · Drug: Cisplatin

  • Placebo comparator
    Arm B (Placebo+Chemotherapy)

    Participants receive placebo to pembrolizumab, 200 mg IV infusion, every 3 weeks (Q3W), Day 1 of each 3-week cycle for up to 35 cycles PLUS gemcitabine, 1000 mg/m\^2 IV infusion, Q3W, Day 1 and Day 8 of each 3-week cycle until progressive disease or unacceptable toxicity PLUS cisplatin, 25 mg/m\^2 IV infusion, Q3W, Day 1 and Day 8 of each 3-week cycle for up to 8 cycles.

    Drug: Gemcitabine · Drug: Cisplatin · Drug: Placebo

Interventions

  • BiologicalPembrolizumab

    Pembrolizumab by intravenous (IV) infusion

    Also known as: MK-3475

  • Gemcitabine by IV infusion

    Also known as: Gemzar

  • Cisplatin by IV infusion

    Also known as: Platinol®, Platinol®-AQ

  • DrugPlacebo

    Placebo to pembrolizumab

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    Overall survival was defined as the time from randomization to death due to any cause.

    Time frame: Up to approximately 38 months

Secondary outcomes

  1. Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (BICR)

    PFS was defined as the time from randomization to the first documented disease progression (PD) or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. PFS as assessed by BICR per RECIST 1.1 was presented.

    Time frame: Up to approximately 26 months

  2. Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)

    ORR was defined as the percentage of participants who have a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: a ≥30% decrease in the sum of diameters \[SOD\] of target lesions) as assessed by BICR per RECIST 1.1, which was adjusted for this study to allow a maximum of 10 target lesions in total and 5 per organ.

    Time frame: Up to approximately 26 months

  3. Duration of Response (DOR) Per RECIST 1.1 as Assessed by BICR

    For participants who demonstrated a confirmed CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR was defined as the time from first documented evidence of a CR or PR until PD or death. DOR for participants who had not progressed or died at the time of analysis was to be censored at the date of their last tumor assessment. Per RECIST 1.1, PD was defined as at least a 20% increase in the sum of diameters of target lesions as well as an absolute increase of at least a 5 mm in the sum of diameters. The appearance of one or more new lesions was also considered PD. DOR assessments were based on BICR with confirmation. The DOR as assessed using RECIST 1.1 for all participants who experienced a confirmed CR or PR was presented.

    Time frame: Up to approximately 38 months

  4. Number of Participants Who Experience One or More Adverse Events (AE)

    An adverse event (AE) was defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it was considered related to the medical treatment or procedure, that occurred during the course of the study. Number of participants who experienced one or more AEs were reported.

    Time frame: Up to approximately 65 months

  5. Number of Participants Who Discontinued Study Intervention Due to an AE

    An AE was defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it was considered related to the medical treatment or procedure, that occurs during the course of the study. Number of participants who discontinued study intervention due to an AE were reported.

    Time frame: Up to approximately 63 months

07

Results

Posted Dec 22, 2023

Participant flow

Participant flow — Overall Study
MilestoneArm A: Pembrolizumab + ChemotherapyArm B: Placebo + Chemotherapy
Started533536
Treated529534
Received a second course of pembrolizumab100
Completed00
Not completed533536
Withdrew: Death482504
Withdrew: Lost to follow-up10
Withdrew: Withdrawal by subject74
Withdrew: Sponsor decision4328

Outcome measures

PrimaryOverall Survival (OS)

Overall survival was defined as the time from randomization to death due to any cause.

Time frame:
Up to approximately 38 months
Reported as:
Median · Months
Overall Survival (OS)
MonthsArm A: Pembrolizumab + ChemotherapyArm B: Placebo + Chemotherapy
Overall Survival (OS)12.7 (11.5 to 13.6)10.9 (9.9 to 11.6)
Statistical analysis
  • Arm A: Pembrolizumab + Chemotherapy vs Arm B: Placebo + Chemotherapy · Log Rank · p = 0.0034 (One-sided p-value was calculated based on log rank test.) · Hazard ratio (hr): 0.83 · 95% CI 0.72 to 0.95Hazard Ratio (HR) and associated 95% confidence interval (CI) was calculated using Cox regression model with Efron's method of tie handling with treatment as a covariate.
SecondaryProgression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (BICR)

PFS was defined as the time from randomization to the first documented disease progression (PD) or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. PFS as assessed by BICR per RECIST 1.1 was presented.

Time frame:
Up to approximately 26 months
Reported as:
Median · Months
Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (BICR)
MonthsArm A: Pembrolizumab + ChemotherapyArm B: Placebo + Chemotherapy
Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (BICR)6.5 (5.7 to 6.9)5.6 (5.1 to 6.6)
Statistical analysis
  • Arm A: Pembrolizumab + Chemotherapy vs Arm B: Placebo + Chemotherapy · Log Rank · p = 0.0225 (One-sided p-value was calculated based on log rank test.) · Hazard ratio (hr): 0.86 · 95% CI 0.75 to 1.00HR and associated 95% CI were calculated using Cox regression model with Efron's method of tie handling with treatment as a covariate.
SecondaryObjective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)

ORR was defined as the percentage of participants who have a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: a ≥30% decrease in the sum of diameters \[SOD\] of target lesions) as assessed by BICR per RECIST 1.1, which was adjusted for this study to allow a maximum of 10 target lesions in total and 5 per organ.

Time frame:
Up to approximately 26 months
Reported as:
Number · Percentage of Participants
Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)
Percentage of ParticipantsArm A: Pembrolizumab + ChemotherapyArm B: Placebo + Chemotherapy
Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)28.7 (24.9 to 32.8)28.5 (24.8 to 32.6)
Statistical analysis
  • Arm A: Pembrolizumab + Chemotherapy vs Arm B: Placebo + Chemotherapy · Miettinen & Nurminen · p = 0.4735 (One-sided p-value was based on Miettinen \& Nurminen method.) · Difference in percentages: 0.2 · 95% CI -5.2 to 5.6Difference in percentage was calculated using Miettinen \& Nurminen method. Difference in percentage=Arm A minus Arm B
SecondaryDuration of Response (DOR) Per RECIST 1.1 as Assessed by BICR

For participants who demonstrated a confirmed CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR was defined as the time from first documented evidence of a CR or PR until PD or death. DOR for participants who had not progressed or died at the time of analysis was to be censored at the date of their last tumor assessment. Per RECIST 1.1, PD was defined as at least a 20% increase in the sum of diameters of target lesions as well as an absolute increase of at least a 5 mm in the sum of diameters. The appearance of one or more new lesions was also considered PD. DOR assessments were based on BICR with confirmation. The DOR as assessed using RECIST 1.1 for all participants who experienced a confirmed CR or PR was presented.

Time frame:
Up to approximately 38 months
Reported as:
Median · Months
Duration of Response (DOR) Per RECIST 1.1 as Assessed by BICR
MonthsArm A: Pembrolizumab + ChemotherapyArm B: Placebo + Chemotherapy
Duration of Response (DOR) Per RECIST 1.1 as Assessed by BICR8.3 (6.9 to 10.2)6.8 (5.7 to 7.1)
SecondaryNumber of Participants Who Experience One or More Adverse Events (AE)

An adverse event (AE) was defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it was considered related to the medical treatment or procedure, that occurred during the course of the study. Number of participants who experienced one or more AEs were reported.

Time frame:
Up to approximately 65 months
Reported as:
Count of participants · Participants
Number of Participants Who Experience One or More Adverse Events (AE)
ParticipantsArm A: Pembrolizumab + ChemotherapyArm B: Placebo + Chemotherapy
Number of Participants Who Experience One or More Adverse Events (AE)524532
SecondaryNumber of Participants Who Discontinued Study Intervention Due to an AE

An AE was defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it was considered related to the medical treatment or procedure, that occurs during the course of the study. Number of participants who discontinued study intervention due to an AE were reported.

Time frame:
Up to approximately 63 months
Reported as:
Count of participants · Participants
Number of Participants Who Discontinued Study Intervention Due to an AE
ParticipantsArm A: Pembrolizumab + ChemotherapyArm B: Placebo + Chemotherapy
Number of Participants Who Discontinued Study Intervention Due to an AE140125

Adverse events

Collected over Up to approximately 65 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
First Course: Arm A: Pembrolizumab + Chemotherapy483/533 (90.6%)280/529 (52.9%)513/529 (97%)
First Course: Arm B: Placebo + Chemotherapy505/536 (94.2%)264/534 (49.4%)522/534 (97.8%)
Second Course: Arm A: Pembrolizumab + Chemotherapy4/10 (40%)0/10 (0%)10/10 (100%)
Most frequent serious events
Showing 10 of 314
Most frequent serious events
EventFirst Course: Arm A: Pembrolizumab + ChemotherapyFirst Course: Arm B: Placebo + ChemotherapySecond Course: Arm A: Pembrolizumab + Chemotherapy
CholangitisHepatobiliary disorders31/52924/5340/10
PyrexiaGeneral disorders30/52912/5340/10
Platelet count decreasedInvestigations19/52910/5340/10
Biliary tract infectionInfections and infestations17/52918/5340/10
Biliary obstructionHepatobiliary disorders12/52916/5340/10
SepsisInfections and infestations13/52916/5340/10
AnaemiaBlood and lymphatic system disorders13/52910/5340/10
AscitesGastrointestinal disorders6/52913/5340/10
Neutrophil count decreasedInvestigations11/5291/5340/10
Pulmonary embolismRespiratory, thoracic and mediastinal disorders11/5298/5340/10
Most frequent other events
Showing 10 of 69
Most frequent other events
EventFirst Course: Arm A: Pembrolizumab + ChemotherapyFirst Course: Arm B: Placebo + ChemotherapySecond Course: Arm A: Pembrolizumab + Chemotherapy
Neutrophil count decreasedInvestigations328/529327/5342/10
AnaemiaBlood and lymphatic system disorders315/529307/5340/10
NauseaGastrointestinal disorders233/529248/5343/10
Platelet count decreasedInvestigations208/529212/5341/10
ConstipationGastrointestinal disorders185/529189/5343/10
FatigueGeneral disorders187/529172/5341/10
Decreased appetiteMetabolism and nutrition disorders142/529152/5341/10
White blood cell count decreasedInvestigations141/529127/5340/10
VomitingGastrointestinal disorders120/529128/5340/10
PyrexiaGeneral disorders119/52996/5340/10

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Arm A: Pembrolizumab + ChemotherapyArm B: Placebo + ChemotherapyTotal
Mean63.3 ± 10.361.8 ± 11.062.5 ± 10.7
Sex: Female, Male
Sex: Female, Male(Participants)Arm A: Pembrolizumab + ChemotherapyArm B: Placebo + ChemotherapyTotal
Female253264517
Male280272552
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm A: Pembrolizumab + ChemotherapyArm B: Placebo + ChemotherapyTotal
Hispanic or Latino5952111
Not Hispanic or Latino433449882
Unknown or Not Reported413576
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm A: Pembrolizumab + ChemotherapyArm B: Placebo + ChemotherapyTotal
American Indian or Alaska Native213
Asian245250495
Native Hawaiian or Other Pacific Islander101
Black or African American11314
White256268524
More than one race527
Unknown or Not Reported131225
Geographic Region
Geographic Region(Participants)Arm A: Pembrolizumab + ChemotherapyArm B: Placebo + ChemotherapyTotal
Asian242244486
Non-Asian291292583
Disease Status
Disease Status(Participants)Arm A: Pembrolizumab + ChemotherapyArm B: Placebo + ChemotherapyTotal
Locally Advanced6066126
Metastatic473470943
Site of Origin
Site of Origin(Participants)Arm A: Pembrolizumab + ChemotherapyArm B: Placebo + ChemotherapyTotal
Gallbladder115118233
Intrahepatic320313633
Extrahepatic98105203
08

Study locations

185 sites
  • University of Alabama at Birmingham Comprehensive Cancer Ctr ( Site 0016)
    Birmingham, Alabama 35294, United States
  • University of California San Diego Moores Cancer Center ( Site 0008)
    La Jolla, California 92093-0698, United States
  • UCLA Hematology/Oncology - Santa Monica ( Site 0014)
    Los Angeles, California 90404, United States
  • University of California - San Francisco ( Site 0030)
    San Francisco, California 94158, United States
  • University of Colorado Hospital ( Site 0011)
    Aurora, Colorado 80045, United States
  • Hartford Hospital ( Site 0057)
    Hartford, Connecticut 06102, United States
  • Yale University ( Site 0053)
    New Haven, Connecticut 06510, United States
  • Winship Cancer Institute of Emory University ( Site 0013)
    Atlanta, Georgia 30322-1013, United States
  • Northwest Georgia Oncology Centers PC ( Site 0045)
    Marietta, Georgia 30060, United States
  • Decatur Memorial Hospital ( Site 0056)
    Decatur, Illinois 62526, United States
  • Winthrop University Hospital ( Site 0059)
    Mineola, New York 11501, United States
  • Laura and Isaac Perlmutter Cancer Center at NYU Langone Health ( Site 0038)
    New York, New York 10016, United States
  • Columbia University/Herbert Irving Cancer Center ( Site 0009)
    New York, New York 10032, United States
  • University of Oklahoma- Stephenson Oklahoma Cancer Center ( Site 0055)
    Oklahoma City, Oklahoma 73104, United States
  • OHSU Center for Health & Healing ( Site 0044)
    Portland, Oregon 97239, United States
  • Charleston Oncology ( Site 0042)
    Charleston, South Carolina 29414, United States
  • Saint Francis Health System ( Site 0051)
    Greenville, South Carolina 29607, United States
  • Blue Ridge Cancer Care ( Site 0033)
    Roanoke, Virginia 24014, United States
  • CEMIC ( Site 0581)
    Buenos Aires, Buenos Aires F.D. C1431FWO, Argentina
  • Fundacion Favaloro ( Site 0578)
    Ciudad de Buenos Aires, Buenos Aires F.D. C1093AAS, Argentina
  • Centro Medico San Roque ( Site 0579)
    San Miguel de Tucumán, Tucumán Province T4000IAK, Argentina
  • Hospital Municipal de Gastroenterologia Dr. Bonorino Udaondo ( Site 0580)
    CABA, C1264AAA, Argentina
  • Centro Oncologico Riojano Integral ( Site 0584)
    La Rioja, F5300COE, Argentina
  • Liverpool Hospital ( Site 0707)
    Liverpool, New South Wales 2170, Australia
  • Mid North Coast Cancer Institute ( Site 0708)
    Port Macquarie, New South Wales 2444, Australia
  • Gallipoli Medical Research Foundation ( Site 0705)
    Brisbane, Queensland 4120, Australia
  • Eastern Health ( Site 0704)
    Box Hill, Victoria 3128, Australia
  • Western Health-Sunshine Hospital ( Site 0709)
    St Albans, Victoria 3021, Australia
  • UZA University Hospital Antwerp ( Site 0202)
    Edegem, Antwerpen 2650, Belgium
  • Erasme Hospital ( Site 0204)
    Brussels, Bruxelles-Capitale, Region de 1070, Belgium
  • Saint-Luc UCL ( Site 0200)
    Brussels, Bruxelles-Capitale, Region de 1200, Belgium
  • Grand Hopital de Charleroi ( Site 0206)
    Charleroi, Hainaut 6000, Belgium
  • CHU de Liege ( Site 0201)
    Liège, Liege 4000, Belgium
  • UZ Gent ( Site 0203)
    Ghent, Oost-Vlaanderen 9000, Belgium
  • UZ Leuven ( Site 0205)
    Leuven, Vlaams-Brabant 3000, Belgium
  • Oncobio Servicos de Saude SA ( Site 0604)
    Nova Lima, Minas Gerais 34000-000, Brazil
  • Hospital de Caridade de Ijui ( Site 0602)
    Ijuí, Rio Grande do Sul 98700-000, Brazil
  • Associacao Hospitalar Moinhos de Vento ( Site 0599)
    Porto Alegre, Rio Grande do Sul 90035-001, Brazil
  • Hospital de Clinicas de Porto Alegre ( Site 0610)
    Porto Alegre, Rio Grande do Sul 90035-903, Brazil
  • Hospital Nossa Senhora da Conceicao ( Site 0601)
    Porto Alegre, Rio Grande do Sul 91350-200, Brazil
  • Instituto COI de Pesquisa Educacao e Gestao ( Site 0606)
    Rio de Janeiro, 22793-080, Brazil
  • Instituto do Cancer do Estado de Sao Paulo - ICESP ( Site 0607)
    São Paulo, 01246-000, Brazil
  • Hospital Paulistano - Amil Clinical Research ( Site 0603)
    São Paulo, 01321-001, Brazil
  • Real e Benemerita Associacao Portuguesa de Beneficencia ( Site 0609)
    São Paulo, 01321-001, Brazil
  • A.C. Camargo Cancer Center ( Site 0600)
    São Paulo, 01509-900, Brazil
  • Tom Baker Cancer Centre ( Site 0184)
    Calgary, Alberta T2N 4N2, Canada
  • Cross Cancer Institute ( Site 0183)
    Edmonton, Alberta T6G 1Z2, Canada
  • Hamilton Health Sciences-Juravinski Cancer Centre ( Site 0182)
    Hamilton, Ontario L8V5C2, Canada
  • Centre Hospitalier de l Universite de Montreal - CHUM ( Site 0180)
    Montreal, Quebec H2X 3E4, Canada
  • McGill University Health Centre ( Site 0179)
    Montreal, Quebec H4A 3J1, Canada
  • Centro Investigación del Cáncer James Lind ( Site 0622)
    Temuco, Araucania 4780000, Chile
  • IC La Serena Research ( Site 0630)
    La Serena, Coquimbo Region 1720430, Chile
  • Servicios Medicos Urumed ( Site 0621)
    Rancagua, Lbtdr Gen Bernardo O Higgins 2852424, Chile
  • Fundacion Arturo Lopez Perez FALP ( Site 0623)
    Santiago, Region M. de Santiago 7500921, Chile
  • Sociedad Oncovida S.A. ( Site 0626)
    Santiago, Region M. de Santiago 7510032, Chile
  • Pontificia Universidad Catolica de Chile ( Site 0620)
    Santiago, Region M. de Santiago 8330032, Chile
  • Anhui Provincial Hospital ( Site 0140)
    Hefei, Anhui 230001, China
  • Beijing Cancer Hospital ( Site 0138)
    Beijing, Beijing Municipality 100036, China
  • Peking Union Medical College Hospital ( Site 0150)
    Beijing, Beijing Municipality 100730, China
  • First Affiliated Hospital of The Third Military Medical University ( Site 0130)
    Chongqing, Chongqing Municipality 400038, China
  • Fujian Provincial Cancer Hospital ( Site 0154)
    Fuzhou, Fujian 350014, China
  • 900 Hospital of the Joint ( Site 0137)
    Fuzhou, Fujian 350025, China
  • Guangdong Provincial People s Hospital ( Site 0161)
    Guangzhou, Guangdong 510080, China
  • The Third Xiangya Hospital of Central South University ( Site 0157)
    Changsha, Hainan 410013, China
  • Harbin Medical University Cancer Hospital ( Site 0133)
    Harbin, Heilongjiang 610000, China
  • Hunan Provincial People Hospital ( Site 0142)
    Changsha, Hunan 410005, China
  • Hunan Cancer Hospital ( Site 0132)
    Changsha, Hunan 410013, China
  • The 81st Hospital of PLA ( Site 0128)
    Nanjing, Jiangsu 210031, China
  • The First Hospital of Jilin University ( Site 0131)
    Changchun, Jilin 130021, China
  • Zhongshan Hospital Fudan University ( Site 0129)
    Shanghai, Shanghai Municipality 200032, China
  • Renji Hospital Shanghai Jiaotong University School of Medicine ( Site 0158)
    Shanghai, Shanghai Municipality 200127, China
  • Fudan University Shanghai Cancer Center ( Site 0160)
    Shanghai, Shanghai Municipality 201315, China
  • Tangdu Hospital ( Site 0146)
    Xi’an, Shanxi 710038, China
  • The First Affiliated Hospital of Xi an Jiaotong University ( Site 0145)
    Xi’an, Shanxi 710048, China
  • West China Hospital of Sichuan University ( Site 0147)
    Chengdu, Sichuan 610041, China
  • Tianjin Medical University Cancer Institute & Hospital ( Site 0155)
    Tianjin, Tianjin Municipality 300060, China
  • The First Affiliated Hospital Zhejiang University ( Site 0136)
    Hangzhou, Zhejiang 310003, China
  • Zhejiang Cancer Hospital ( Site 0134)
    Hangzhou, Zhejiang 310022, China
  • CHU Bordeaux Haut-Leveque Centre Francois Magendie ( Site 0245)
    Pessac, Gironde 33604, France
  • A.P.H. Paris, Hopital Beaujon ( Site 0247)
    Clichy, Hauts-de-Seine 92110, France
  • CHU de Montpellier - Hopital Saint-Eloi ( Site 0248)
    Montpellier, Herault 34295, France
  • Centre Eugene Marquis ( Site 0242)
    Rennes, Ille-et-Vilaine 35042, France
  • CHU Clermont-Ferrand - Site Estaing ( Site 0249)
    Clermont-Ferrand, Puy-de-Dome 63003, France
  • Gustave Roussy ( Site 0244)
    Villejuif, Val-de-Marne 94805, France
  • Universitaetsklinikum Ulm ( Site 0267)
    Ulm, Baden-Wurttemberg 89081, Germany
  • Klinikum der Ludwig - Maximilian Universitat Munchen ( Site 0264)
    Munich, Bavaria 81377, Germany
  • Krankenhaus Nordwest ( Site 0266)
    Frankfurt am Main, Hesse 60488, Germany
  • Medizinische Hochschule Hannover ( Site 0265)
    Hanover, Lower Saxony 30625, Germany
  • Universitaetsklinikum Aachen AOER ( Site 0275)
    Aachen, North Rhine-Westphalia 52074, Germany
  • Universitaetsklinikum Koeln ( Site 0274)
    Cologne, North Rhine-Westphalia 50937, Germany
  • Universitaetsklinikum Essen ( Site 0273)
    Essen, North Rhine-Westphalia 45147, Germany
  • Staedtisches Klinikum Dresden ( Site 0272)
    Dresden, Saxony 01067, Germany
  • Universitaetsklinikum Magdeburg A.o.R. ( Site 0271)
    Magdeburg, Saxony-Anhalt 39120, Germany
  • Charite - Universtitatsmedizin Berlin CCM ( Site 0269)
    Berlin, 10117, Germany
  • Universitaetsklinikum Hamburg-Eppendorf ( Site 0268)
    Hamburg, 20246, Germany
  • Pamela Youde Nethersole Eastern Hospital ( Site 0857)
    Hong Kong, Hong Kong
  • Prince of Wales Hospital ( Site 0855)
    Hong Kong, Hong Kong
  • Princess Margaret Hospital. ( Site 0856)
    Hong Kong, Hong Kong
  • Queen Mary Hospital ( Site 0851)
    Hong Kong, Hong Kong
  • Queen Elizabeth Hospital. ( Site 0854)
    Kowloon, Hong Kong

Showing the first 100 of 185 sites across 24 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Kelley RK, Ueno M, Yoo C, Finn RS, Furuse J, Ren Z, Yau T, Klumpen HJ, Chan SL, Ozaka M, Verslype C, Bouattour M, Park JO, Barajas O, Pelzer U, Valle JW, Yu L, Malhotra U, Siegel AB, Edeline J, Vogel A; KEYNOTE-966 Investigators. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023 Jun 3;401(10391):1853-1865. doi: 10.1016/S0140-6736(23)00727-4. Epub 2023 Apr 16. PubMed 37075781 ↗
  • Ren Z, Liang T, Gu S, Gou H, Peng C, Pan Y, Song T, Su H, Cao K, Liang H, Ying J, Geng Z, Yu W, Zhao H, Bai Y, Hao C, Mao Y, Li W, Wang L, Li D, Wang W, Li N, Malhotra U, Qin S. First-Line Pembrolizumab Plus Chemotherapy for Advanced Biliary Tract Cancer: China Subgroup Analysis of the Randomized Phase 3 KEYNOTE-966 Study. Adv Ther. 2026 May 23. doi: 10.1007/s12325-026-03578-4. Online ahead of print. PubMed 42176183 ↗
  • Jiang C, Zhou K, Shu P. Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line treatment for advanced biliary tract cancer: perspectives from US and Chinese payers. BMJ Open. 2025 Apr 23;15(4):e094047. doi: 10.1136/bmjopen-2024-094047. PubMed 40268484 ↗
  • Luo X, Cai T, Wu J, Li X, Wang X, Ma H. Cost-effectiveness of pembrolizumab plus chemotherapy vs. chemotherapy as first-line treatment for advanced biliary tract cancer in China and the US. Front Pharmacol. 2024 Aug 14;15:1393559. doi: 10.3389/fphar.2024.1393559. eCollection 2024. PubMed 39206260 ↗
  • Keller HR, Fluke L, Forrester JA, Wolf RF. Identifying Indications for Neoadjuvant Therapy in Cholangiocarcinoma. Oncology (Williston Park). 2024 Apr 11;38(4):160-162. doi: 10.46883/2024.25921017. PubMed 38661512 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2019 to primary completion in Dec 2022, 38 months.

Results were first posted in Dec 2023, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2019
First posted
Jul 1, 2019
StartActual
Sep 24, 2019
Primary completionActual
Dec 15, 2022
CompletionActual
Apr 1, 2025
Results first posted
Dec 22, 2023
Last update
Mar 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04003636
Responsible party
Sponsor
First posted
Jul 1, 2019
Start date
Sep 24, 2019
Primary completion
Dec 15, 2022
Completion
Apr 1, 2025
Results posted
Dec 22, 2023
Last update
Mar 24, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pembrolizumab

Start the discussion